Unexpected drug interactions and adverse events with antiretroviral drugs

Lancet

Volumn 364, Issue 9428, 2004, Pages 8-10

  Moyle, Graeme ^a   Boffito, Marta ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADEFOVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; CIDOFOVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; FIBRIC ACID DERIVATIVE; FISH OIL; GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYUREA; INDINAVIR; LAMIVUDINE; LOPINAVIR; METFORMIN; NELFINAVIR; NICOTINIC ACID; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; STEROID; TAMOXIFEN; TENOFOVIR; ZALCITABINE; ZIDOVUDINE; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG DERIVATIVE; ORGANOPHOSPHORUS COMPOUND; PHOSPHONIC ACID DERIVATIVE;

ANEMIA; BONE NECROSIS; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; DIABETES MELLITUS; DIARRHEA; DYSLIPIDEMIA; ECTODERMAL DYSPLASIA; GLUCOSE INTOLERANCE; GYNECOMASTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERAMYLASEMIA; HYPERLACTATEMIA; HYPERLIPIDEMIA; HYPERSENSITIVITY REACTION; INSULIN RESISTANCE; KIDNEY DISEASE; LACTIC ACIDOSIS; LIPID STORAGE; LIPOATROPHY; NAUSEA; NONHUMAN; NOTE; PANCREATITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; SEXUAL DYSFUNCTION; SLEEP DISORDER; SUBCUTANEOUS FAT DISORDER; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; DRUG INTERACTION; RISK FACTOR;

ADENINE; ANTI-HIV AGENTS; DIDANOSINE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; ORGANOPHOSPHORUS COMPOUNDS; PANCREATITIS; PERIPHERAL NERVOUS SYSTEM DISEASES; PHOSPHONIC ACIDS; RISK FACTORS;

EID: 3042784340     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)16608-7     Document Type: Note

References (19)

1. Moyle G. Double "d" drug danger. AIDS Read 2003; 13: 15-16, 23-24
2. Pozniak A, Gazzard B, Anderson J, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med. 4:(suppl 1):2003;1-41
3. Yarchoan R, Mitsuya H, Pluda JM, et al. The National Cancer Institute phase I study of 2′,3′-dideoxyinosine administration in adults with AIDS or AIDS-related complex: analysis of activity and toxicity profiles. Rev Infect Dis. 12:(suppl 5):1990;S522-533
4. Anonymous. Didanosine and ACTG 116A. Lancet 1993; 341: 109.
5. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection: the NIAID AIDS Clinical Trials Group. N Engl J Med. 327:1992;581-587
6. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimetre: AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med. 335:1996;1081-1090
7. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348: 283-291.
8. Grady T, Saluja AK, Steer ML, Lerch MM, Modlin IM, Powers RE. In vivo and in vitro effects of the azidothymidine analog dideoxyinosine on the exocrine pancreas of the rat. J Pharmacol Exp Ther. 262:1992;445-449
9. Czako L, Takacs T, Varga IS, et al. Involvement of oxygen-derived free radicals in L-arginine-induced acute pancreatitis. Dig Dis Sci. 43:1998;1770-1777
10. Tay LK, Papp EA, Timoszyk J. Metabolism of 14C-2′,3′- dideoxyinosine by the in situ perfused rat liver preparation. Biopharm Drug Dispos. 12:1991;285-297
11. Folch E, Gelpi E, Rosello-Catafau J, Closa D. Free radicals generated by xanthine oxidase mediate pancreatitis-associated organ failure. Dig Dis Sci. 43:1998;2405-2410
12. Lake-Bakaar G, Mazzoccoli V, Dickman K, Lyubsky S. Differential effects of nucleoside analogs on oxidative phosphorylation in human pancreatic cells. Dig Dis Sci. 46:2001;1853-1863
13. st IAS Conference on HIV Pathogenesis and Treatment, July 8-11, 2001, Buenos Aires, Argentina. 2001: 337 (abstr).
14. Kearney BP, Damle B, Plummer A, et al. Tenofovir DF (TDF) and didanosine EC (ddI EC): investigation of pharmacokinetic (PK) drug-drug and drug-food interactions. XIV International AIDS Conference, July 7-12, 2002, Barcelona, Spain. 2002: LBPE9026 (abstr).
15. th Conference of Retroviruses and Opportunistic Infections, Feb 10-14, 2003; Boston, Massachusetts. 2003: 533 (abstr).
16. Rendon A, Barrios A, Gonzalez de Requena D, et al. Didanosine plasma levels in patients taking tenofovir concomitantly: high interindividual variability but association with hyperlactatemia. HIV Med 2004; 5: 233 (abstr 81).
17. Podzamczer D, Ferrer E, Gatell JM, et al. Early virological failure and occurrence of resistance in naive patients receiving tenofovir, didanosine and efavirenz. Antiviral Ther. 9:2004;S172
18. Ray AS, Olson L, Fridland A. Role of purine nucleoside phosphorylase in interactions between 2',3'-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob Agents Chemother. 48:2004;1089-1095
19. Robbins BL, Wilcox CK, Fridland A, Rodman JH. Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells. Pharmacotherapy. 23:2003;695-701